Login
$AZR
$3.81 -$0.28 (6.85%) Live

$AZR 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

AT177 IND submission and Phase 1a initiation on track for the first half of 2027

09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors (the “Board”) of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.) (the “Company”). Dr. H...

28 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

16 Oct 2026 8-K: Other Events

As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it...

02 Oct 2026 8-K: Other Events

As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it...

18 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(a) Successor to Prior Plan. The Plan is the successor to the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; and (ii) all outstanding awards granted under the Prior Plan will remain su...

16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

The following unaudited pro forma condensed financial information presents the historical unaudited consolidated balance sheet as of June 30, 2026 of Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), adjusted to give effect to (i) ...

25 Aug 2026 8-K: Unregistered Sales of Equity Securities

On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. The option...

21 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On August 18, 2026, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Re...

17 Aug 2026 8-K: Results of Operations and Financial Condition

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline

13 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company’s 2026 Annua...

11 Jun 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of June 11, 2026, by and among ADIAL PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), ADIAL MERGER SUB I, INC., a Delaware corporation and wholly owned subs...

11 May 2026 8-K: Results of Operations and Financial Condition

Glen Allen, VA – May 11, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related d...

09 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Restricted Stock Award Agreement (this “Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A, is entered into between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual i...

06 Mar 2026 8-K: Results of Operations and Financial Condition

Glen Allen, VA – March 6, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related ...

03 Mar 2026 8-K: Regulation FD Disclosure; Other Events

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

24 Feb 2026 8-K: Other Events

Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3

04 Feb 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026

06 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 5, 2025, James W. Newman, Jr., a member of the Board of Directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”), notified the Company of his decision to resign, effective immediately, from his position as a memb...

01 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support